Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM1 | Q13255 | 12/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10205807 | 1.00 | GRM1 (0.36) | GRM1EPHX2ADORA3MAPK8MAPK10 | |
| SCHEMBL25498584 | 0.83 | SMN1; SMN2 (0.50) | — | |
| SCHEMBL23156508 | 0.82 | ALDH1A1 (0.32) | EPHX2 | |
| SCHEMBL28003109 | 0.82 | CHRNB2 (0.38) | GRM1EPHX2ADORA3MAPK8MAPK10 | |
| SCHEMBL28034927 | 0.82 | CHRNB2 (0.38) | GRM1EPHX2ADORA3MAPK8MAPK10 | |
| SCHEMBL28034929 | 0.82 | CHRNB2 (0.38) | GRM1EPHX2ADORA3MAPK8MAPK10 | |
| SCHEMBL13165462 | 0.81 | MAPT (0.38) | EPHX2 | |
| SCHEMBL2617044 | 0.81 | MAPT (0.38) | EPHX2 | |
| SCHEMBL76462 | 0.81 | — | — | |
| SCHEMBL13165512 | 0.81 | MAPT (0.38) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018124-A1 | MODULATORS OF FPR1 AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2024-01-18 | — | — | US | disclosed |
| US-20240018124-A1 | MODULATORS OF FPR1 AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2024-01-18 | — | — | US | disclosed |
| US-20240018124-A1 | MODULATORS OF FPR1 AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2024-01-18 | — | — | US | disclosed |
| WO-2018044350-A1 | TARGETING LIGANDS | ARROWHEAD PHARMACEUTICALS, INC (US) | 2018-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018124-A1 | MODULATORS OF FPR1 AND METHODS OF USING THE SAME | FPR1, FPR2, FPR3 | GRM1 119/4885EPHX2 1556/4885ADORA3 1238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.